There are currently six phase III clinical trials evaluating the role of adjuvant mono-immunotherapy in patients with completely resected III-N2 NSCLC, with five of which evaluate anti-PD1 or anti-PD-L1 ICIs (PEARLS, BR31, ANVIL, IMpower010, ALCHEMIST-IO Arm B), including operated patients with stage IIIA-N2 and excluding T3-4N2 tumours, and one of them evaluating the anti-IL1β monoclonal antibody canakinumab in both IIIB-N2 as well as IIIA-N2 patients (CANOPY-A) [41,42,43,44]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.